Modeling of 24-hour glucose and insulin profiles in patients with type 2 diabetes mellitus treated with biphasic insulin aspart

• Published in: Journal of clinical pharmacology Vol. 54; no. 7; p. 809
• Main Authors: Røge, Rikke M, Klim, Søren, Kristensen, Niels R, Ingwersen, Steen H, Kjellsson, Maria C
• Format: Journal Article
• Language: English
• Published: England 01.07.2014
• Subjects: Biphasic Insulins - blood; Biphasic Insulins - pharmacokinetics; Biphasic Insulins - therapeutic use; Blood Glucose - analysis; Circadian Rhythm; Cross-Over Studies; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Double-Blind Method; Drug Administration Schedule; Drug Monitoring - methods; Humans; Hyperglycemia - prevention & control; Hypoglycemic Agents - blood; Hypoglycemic Agents - pharmacokinetics; Hypoglycemic Agents - therapeutic use; Insulin - blood; Insulin Aspart - blood; Insulin Aspart - pharmacokinetics; Insulin Aspart - therapeutic use; Models, Biological; Reproducibility of Results; PK/PD modeling; glucose homeostasis; diabetes; biphasic insulin aspart
• ISSN: 1552-4604
• DOI: 10.1002/jcph.270

Insulin therapy for diabetes patients is designed to mimic the endogenous insulin response of healthy subjects and thereby generate normal blood glucose levels. In order to control the blood glucose in insulin-treated diabetes patients, it is important to be able to predict the effect of exogenous insulin on blood glucose. A pharmacokinetic/pharmacodynamic model for glucose homoeostasis describing the effect of exogenous insulin would facilitate such prediction. Thus the aim of this work was to extend the previously developed integrated glucose-insulin (IGI) model to predict 24-hour glucose profiles for patients with Type 2 diabetes following exogenous insulin administration. Clinical data from two trials were included in the analysis. In both trials, 24-hour meal tolerance tests were used as the experimental setup, where exogenous insulin (biphasic insulin aspart) was administered in relation to meals. The IGI model was successfully extended to include the effect of exogenous insulin. Circadian variations in glucose homeostasis were assessed on relevant parameters, and a significant improvement was achieved by including a circadian rhythm on the endogenous glucose production in the model. The extended model is a useful tool for clinical trial simulation and for elucidating the effect profile of new insulin products.